Top outbound deals by Indian companies: From Tata Steel to Sun Pharma

Sun Pharmaceutical Industries announced the acquisition of US-based Organon & Co. in an all-cash deal valued at approximately USD 11.75 billion (₹98,000 cror...

What Happened

Sun Pharmaceutical Industries announced the acquisition of US-based Organon & Co. in an all-cash deal valued at approximately USD 11.75 billion (₹98,000 crore), making it the largest outbound acquisition by an Indian pharmaceutical company and the largest biopharma deal globally in 2026.
The deal, announced April 26–27, 2026, involves Sun Pharma acquiring all outstanding shares of Organon at USD 14.00 per share.
Organon, spun off from Merck (US) in 2021, specialises in women's health products and biosimilars, with over 70 products sold across 140 countries.
Post-acquisition, Sun Pharma's combined revenues will reach approximately USD 12.4 billion, placing it among the top 25 global pharmaceutical companies and making it the 7th largest biosimilar player globally.
The transaction is expected to close in early 2027, subject to regulatory approvals (including SEBI, Competition Commission of India, US antitrust) and Organon stockholder approval.
This deal is part of a broader trend of Indian companies making large outbound acquisitions — from Tata Steel's Corus acquisition (2007) to Hindalco's Novelis buy (2007) and Tata Motors–JLR (2008).

Static Topic Bridges

Outbound Foreign Direct Investment (OFDI) — India's Regulatory Framework

Overseas investments by Indian companies are regulated under the Foreign Exchange Management (Overseas Investment) Rules, 2022 and the Foreign Exchange Management (Overseas Investment) Regulations, 2022, issued by the Reserve Bank of India (RBI). The framework replaced the earlier FEMA (Transfer or Issue of Foreign Security) Regulations, 2004.

Two routes for overseas investment:
Automatic Route: Investments up to USD 1 billion per financial year (for listed Indian companies: up to 400% of net worth) — no prior RBI approval needed, processed through designated Authorised Dealer (AD) banks
Approval Route: Investments exceeding USD 1 billion per financial year, strategic sector investments, or investments in restricted jurisdictions — require prior RBI approval
Sun Pharma's USD 11.75 billion deal will require RBI approval as it far exceeds the USD 1 billion automatic route threshold
Indian entities must file Form FC on RBI's FIRMS portal within 30 days of investment and submit Annual Performance Reports (APRs)
Regulatory framework: FEMA, 1999 (Foreign Exchange Management Act); RBI Master Directions on Overseas Investment

Connection to this news: The Organon acquisition, being the largest-ever outbound pharma deal, will involve the full regulatory chain — RBI approval, SEBI disclosure (as Sun Pharma is listed), Competition Commission of India, and US/international antitrust clearances.

India's Outbound M&A — Historical Milestones

Indian companies began large-scale overseas acquisitions in the 2000s, driven by surplus capital, access to international debt markets, and strategic need for global scale, technology, or brands.

Tata Steel – Corus Group (2007): USD 12.1 billion — steel sector; transformed Tata Steel into a top-10 global steel producer; Corus was a UK-Dutch company
Hindalco – Novelis (2007): USD 6 billion — aluminium rolled products; made Hindalco the world's largest aluminium rolled products company
Tata Motors – Jaguar Land Rover (2008): USD 2.3 billion — automotive; acquired from Ford; JLR later became highly profitable
Bharti Airtel – Zain Africa (2010): USD 10.7 billion — telecom; expanded Airtel to 15 African countries
Sun Pharma – Organon (2026): USD 11.75 billion — pharma/biosimilars (current transaction)

Connection to this news: The Sun Pharma–Organon deal continues the trajectory of Indian companies moving from domestic champions to global consolidators — with pharmaceuticals now leading the outbound M&A wave as IT/telecom once did.

India's Pharmaceutical Sector — Global Position and Policy Context

India is the world's largest supplier of generic medicines by volume, accounting for approximately 20% of global generic exports. The "pharmacy of the world" designation reflects India's dominance in low-cost production of off-patent molecules. The push into biosimilars (complex biologics) represents the industry's next frontier.

India's pharma market size: ~USD 50 billion (domestic + exports combined, FY25 estimates)
India accounts for ~31% of global generic medicine supply by volume (WHO data)
India supplies ~60% of global vaccines (by volume)
Key regulatory body: Central Drugs Standard Control Organisation (CDSCO) under Ministry of Health
Production Linked Incentive (PLI) Scheme for Pharmaceuticals: ₹15,000 crore outlay to incentivise manufacture of high-value drugs (Key Starting Materials, APIs, complex generics)
Biosimilars: Cheaper biologics made by non-originator companies; India is a growing manufacturer (examples: Biocon, Dr. Reddy's, Sun Pharma)

Connection to this news: Organon's biosimilars portfolio and women's health pipeline directly address Sun Pharma's strategic gap in high-margin, complex biologics — a segment requiring global distribution and regulatory expertise that Organon brings.

Biosimilars — What Are They and Why Do They Matter?

Biosimilars are biological medicines that are highly similar to already-approved reference biological drugs (originators/innovators), with no clinically meaningful differences in safety, purity, or potency. Unlike small-molecule generics, biosimilars require complex manufacturing processes (living cells, precise conditions) and cost 20–30% less than originators.

Regulatory pathway in India: Schedule Y of Drugs and Cosmetics Act + CDSCO Guidelines for Biosimilars (2012, revised 2016)
Regulatory pathway in the US: Biologics Price Competition and Innovation Act (BPCIA), 2009; approved by US FDA
India is among the top producers globally: Insulin biosimilars, trastuzumab (breast cancer), adalimumab (autoimmune conditions)
Organon's biosimilar portfolio includes products in women's health, immunology, and cardiovascular segments across 140 countries
Post-acquisition, Sun Pharma will be the 7th largest biosimilar company globally

Connection to this news: The Organon acquisition is fundamentally a biosimilars and women's health play — positioning Sun Pharma at the intersection of two high-growth global segments where scale and distribution networks are key competitive advantages.

Key Facts & Data

Deal value: USD 11.75 billion (all-cash; ~₹98,000 crore at current rates)
Price per Organon share: USD 14.00
Organon's origin: Spun off from Merck (US) in 2021
Organon's reach: 70+ products, 140 countries; specialises in women's health and biosimilars
Post-deal Sun Pharma revenue: ~USD 12.4 billion (top 25 global pharma)
Sun Pharma biosimilars rank post-deal: 7th globally
Expected deal closure: Early 2027 (subject to regulatory approvals)
Largest previous outbound pharma deal by India: Sun Pharma's own acquisitions (Ranbaxy at USD 4 billion, 2015)
Regulatory oversight: RBI (FEMA ODI Rules 2022), SEBI, CCI, US antitrust
Tata Steel–Corus (2007): USD 12.1 billion — previously India's single largest outbound M&A
Hindalco–Novelis (2007): USD 6 billion
Bharti–Zain Africa (2010): USD 10.7 billion